Difference between revisions of "Protein C, human (Ceprotin)"
Jump to navigation
Jump to search
m |
m |
||
| (One intermediate revision by the same user not shown) | |||
| Line 2: | Line 2: | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
| − | * | + | *2001-07-16: Initial authorization as Ceprotin |
| − | *CEPROTIN is indicated for prophylaxis and treatment of purpura fulminans, coumarin-induced skin necrosis, and venous thrombotic events in patients with severe congenital protein C deficiency. | + | *Uncertain date: CEPROTIN is indicated for prophylaxis and treatment of purpura fulminans, coumarin-induced skin necrosis, and venous thrombotic events in patients with severe congenital protein C deficiency. |
==Also known as== | ==Also known as== | ||
*'''Brand name:''' Ceprotin | *'''Brand name:''' Ceprotin | ||
| + | [[Category:Drugs]] | ||
[[Category:Fractionated plasma products]] | [[Category:Fractionated plasma products]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
Latest revision as of 16:41, 9 May 2023
Human protein C
History of changes in EMA indication
- 2001-07-16: Initial authorization as Ceprotin
- Uncertain date: CEPROTIN is indicated for prophylaxis and treatment of purpura fulminans, coumarin-induced skin necrosis, and venous thrombotic events in patients with severe congenital protein C deficiency.
Also known as
- Brand name: Ceprotin